Crucell Terug naar discussie overzicht

RT Dinsdag 29 augustus - 2006

1. [verwijderd] 29 augustus 2006 06:28

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Goede morgen Crucellers,
   
   Gisteren weer een “saai “ dagje. Zoals zo vele keren was de koers in de eerste handels uren (en het volume) amper van zijn plaats te brengen. Op het forum sloeg zowat de verveling toe.
   Maar later in de middag begon de kentering. De koers ging naar beneden en het volume nam naar verhouding flink toe. Mijns inziens geen best teken. (ook volgens TA aanhangers?).
   
   Er zijn diverse berichten geplaatst aangaande analisten verwachtingen. Ik zal ze niet herhalen.
   Zie o.a. dagdraad van gisteren. Wat echter opvalt, is de enorme diversiteit in de verwachtingen. We praten niet over enkele procenten verschil tussen minima en maxima verwachtingen, maar tussen velen tientallen zo niet meer dan 100% verschil tussen hoog-laag verwachtingen.
   
   Wie moeten we nu geloven? Blijkbaar “weten” de analisten het ook niet en “gokken” sommige maar. Ik geloof echt niet dat hier redelijke calculaties ten grondslag liggen.
   De meningen, en aannames liggen simpelweg te ver uiteen.
   
   Hetzelfde zie je hier op het forum, van hosanna, tot diepe mineur. Nog even en de “waarheid” komt boven tafel. Velen al anticiperend op dit moment hun posities ingenomen c.q. afgebouwd. Wat mij persoonlijk betreft, ik laat het allemaal maar over mij heen komen.
   
   De meningen op dit forum lopen van 1 cent (flip flap/yellowww) tot 1000 euro of meer (trudy etc. in 2010 of wat eerder komt). Het zal wel. Gewoon rustig blijven zitten en niet in paniek raken. Mocht de koers plotseling een dip naar beneden vertonen, dan (weer) een goed aankoopmoment? En als het omhoog gaat, bevestiging dat we toch een goed aandeel in handen hebben? Wie zal het zeggen. Vandaag wordt een dag van huilen of lachen.
   
   De resultaten:
   
   Amsterdam:
   
   CRUCELL (CRXL:AMS) 16,57 (-1,07%)
   Koersgegevens
   Laatste 16,57 Volume 299.209
   Verschil -0,18 Verschil% -1,07%
   Bied 16,56 Laat 16,59
   Aantal Bieden 1.400 Aantal Laten 7.984
   Dag hoog 16,90 Dag laag 16,52
   Open 16,89 Slotkoers 16,75
   
   Tickliste gaf geen “rare” (top)deals aan:
   Zeit…… Kurs… Volumen
   9:03:51 16,80 10000
   17:30:12 16,57 5000
   9:11:37 16,72 5000
   17:30:12 16,57 3771
   16:09:33 16,53 3125
   17:30:12 16,57 3000
   16:27:34 16,65 2409
   15:40:34 16,65 2381
   17:30:12 16,57 2301
   17:22:27 16,57 2000
   16:22:46 16,60 2000
   15:40:46 16,60 1989
   15:23:02 16,73 1954
   16:54:24 16,60 1856
   15:23:16 16,73 1842
   17:30:13 16,57 1713
   17:30:13 16,57 1600
   17:30:13 16,57 1500
   16:26:03 16,65 1500
   15:40:05 16,65 1500
   15:02:35 16,69 1500
   14:59:45 16,70 1500
   15:44:52 16,58 1486
   17:06:53 16,61 1361
   16:00:12 16,58 1300
   14:58:08 16,70 1300
   16:54:53 16,60 1292
   12:28:10 16,76 1143
   12:27:16 16,78 1102
   
   VS:
   
   CRUCELL NV - ADS (CRXL:NAS) 21,20 (-1,17%)($21.20:1.2821 = euro 16.54)
   Koersgegevens
   Laatste 21,20 Volume 70.185
   Verschil -0,25 Verschil% -1,17%
   Bied 17,91 Laat 21,35
   Aantal Bieden 700 Aantal Laten 200
   Dag hoog 21,40 Dag laag 21,05
   Open 21,34 Slotkoers 21,45
   
   Afwachten maar.
   
   Zal Flosz de eerste zijn met de q2 cijfers?
   
   Hans
   
2. max21 29 augustus 2006 07:30

   auteur info

   • max21

     Lid sinds: 01 jan 2000

     Laatste bezoek: 20 aug 2024

   • Aanbevelingen

     Ontvangen: 488

     Gegeven: 272

   •    Aantal posts: 3.454

   Ha Hans,
   
   Ik zit al een tijdje in Crucell alleen niet zo vaak op het forum hier maar wat me opvalt bij het lijstje van de koers in de USA dat het verschil tussen de bied en laat zo groot is?
   Afijn, het zal wel aan de dunne handel liggen.
   
   Succes vandaag.
   Groet,
   Max
3. [verwijderd] 29 augustus 2006 08:04

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   29-08-2006 08:02:34 CRUCELL: OMZET 2eKW 2006 EUR 18,9 MLN; VERW. EUR 27,7 MLN
   CRUCELL ZIET NOG STEEDS CASH BURN 2006 EUR 33-38 MLN 08:03:03
   CRUCELL ZIET NOG STEEDS OMZET 2006 EUR 130-150 MLN 08:02:58
   CRUCELL: VERLIES 2eKW '06 EUR 25,7 MLN; VERW. EUR 16,7 MLN
   
   CRUCELL HERHAALT VERWACHTING BREAK EVEN IN 2007
4. [verwijderd] 29 augustus 2006 08:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Published: 08:00 29.08.2006 GMT+2 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562
   
   Crucell Announces Second Quarter 2006 Results
   
   Leiden, The Netherlands, August 29, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, SWX: CRX) today announced its financial results for the first half-year ended June 30, 2006, based on International Financial Reporting Standards (IFRS).
   
   Total revenues for the second quarter were €18.9 million and other operating income was €2.8 million. Net loss for the second quarter of 2006 attributable to equity holders of the parent amounted to €25.7 million. Total revenues for the six months ended June 30, 2006, were €30.6 million; other operating income amounted to €4.8 million for the first six months of 2006. Net loss for the first six months of 2006 attributable to equity holders of the parent amounted to €40.4 million.
   
   Cash and cash equivalents were €177.7 million on June 30, 2006, compared to €178.7 million at the end of the first quarter. Proceeds from the sale of discontinued operations and a reclassification of short-term financial assets to cash, offset cash used in operations in the second quarter. Total assets on June 30, 2006, were €616.1 million.
   
   Crucell's Chief Financial Officer Leonard Kruimer said: "The second quarter results are in line with our expectations as they reflect the effects of purchase price allocation, one-time integration costs, and fully integrated R&D and SG&A costs. Product sales in our Berna subsidiary were up 9% over the same six-month period last year. Given the strong seasonal pattern of these sales, and the expected launch of Quinvaxem(TM), we reiterate our previous guidance for full-year revenue and cash burn: revenue, including other operating income, of €130 to €150 million, with 2006 operational cash burn in the range of €33 to €38 million."
   
   
   Operational Review Second Quarter 2006
   
   * Berna Biotech Acquisition: Crucell's offer for Berna Biotech AG was settled on February 22, 2006. The Company now holds 98.4% of all issued Berna shares. The Company is in the process of delisting the remaining shares, which is expected to be completed in the fourth quarter.
   
   * Quinvaxem: The Korea Food and Drug Administration (KFDA) awarded licensure to Quinvaxem(TM), a fully liquid pentavalent vaccine co-developed with Chiron Corporation, in March 2006. Crucell has started production of the vaccine in Korea and first shipments will be made once pre-qualification is received from the WHO.
   
   * Divestments: Crucell concluded the sale of Rhein Biotech GmbH and veterinary pharmaceuticals company Dr. E. Gräub AG. These divestments enabled Crucell to align its portfolio of activities with its strategic priorities. Total proceeds amounted to €15.4 million.
   
   * Avian influenza vaccine clinical trial: Crucell announced the start of a clinical trial, performed in collaboration with the University of Leicester, UK, testing three types of vaccines against the H9N2 avian influenza virus in humans. The trial involves the vaccination of 560 healthy adults, and will allow Crucell to choose the best vaccine modality for further clinical studies with pandemic flu vaccines. First results of the study are expected by the end of 2006.
   
   * Patent infringement: Crucell settled its patent infringement proceedings against CEVEC Pharmaceuticals GmbH. The final claim in the case was withdrawn following CEVEC's commitment not to use its cell bank in any way that would constitute further infringement of Crucell's European PER.C6® patent.
   
   * STAR(TM) Technology: Crucell signed a non-exclusive STAR(TM) research license agreement with Cambridge, Massachusetts-based Millennium Pharmaceuticals Corporation.
   
   * PER.C6® Licensing: Crucell secured new PER.C6® licensing deals with Upstate USA, BIOA&D and Immuno-Biological Laboratories during the second quarter.
   
   * PER.C6® R&D Center: Crucell and technology partner DSM Biologics announced the establishment of a new PER.C6® R&D Center in Cambridge, Massachusetts, and the appointment of Dr Marco Cacciuttolo as CEO. Operations are expected to commence by the end of 2006.
   
   * Supervisory Board: Mr. Pieter Strijkert, chairman of Crucell's Supervisory Board since the Company's incorporation, stepped down at the Annual General Meeting of Shareholders on June 2, 2006. He was succeeded by the vice-chairman of the Supervisory Board, Mr. Jan Oosterveld.
   
   * Suspension of Aerugen® clinical development: On July 18, 2006, the Company announced the suspension of the clinical development program for Aerugen®, a vaccine for the prevention of Pseudomonas aeruginosa infection.
   
   
   Details of the Financial Results First Half-Year
   
   Revenues and Other Operating Income
   Revenues for the first half-year of 2006 were €30.6 million, compared to €13.4 million in the same period last year. Revenues consist of product sales, license revenues and service fees. Revenues in 2006 represent product sales from Berna from the moment of acquisition at February 22, 2006; license revenues and service fees do not include sales from Berna and are therefore included for six months. Product revenues amount to €21.5 million, concentrated in pediatric and travel vaccines. Product revenues are seasonal and have historically been concentrated in the second half of the year. This is due to seasonal sales of influenza vaccine, and the projected sales of the new Quinvaxem(TM) pediatric vaccine. Comparable product sales from Berna in the first half-year 2006 were up 9% over same period last year.
   
   License revenues were €4.6 million, a decrease of €3.7 million over last year. Last year's license revenues included a €2 million milestone and a significant €2 million up-front fee from a partner. License revenue consisted of initial payments from new contracts as well as annual and other payments on existing contracts. Service fees amount to €4.5 million, compared to €5.1 million last year, which represents a slight decrease in chargeable development activities. Service fees represent revenues for product development activities performed under contracts with partners and licensees.
   
   Other Operating income was €4.8 million, compared to €2.6 million in the same period last year. Other operating income consists of government grants, which increased slightly to €3.0 million, and other income of €1.8 million.
   
   Cost of Goods Sold
   Cost of goods sold for the first six months of 2006 amounted to €27.4 million, €24.2 million of which represents product costs and the remainder of €3.2 million represents costs of service activities. The €24.2 million in product costs is relatively high since it includes a €6.4 million inventory purchase price allocation charge. The remaining step-up in inventory on June 30, 2006, as a result of the purchase price allocation, amounts to €11 million, which will be charged to cost of goods sold in future accounting periods.
   
   Expenses
   Total expenses consist of research and development (R&D) expenses and selling, general and administrative (SG&A) expenses. Total R&D and SG&A expenses were €48.6 for the first six months of 2006. That represents a €27.1 million increase over the same period last year. The difference is primarily attributable to combining activities of Crucell and Berna since acquisition.
   
   R&D expenses amounted to €29.8 million, which represents a €16.3 million increase over the first half of 2005. Berna clinical p
5. [verwijderd] 29 augustus 2006 08:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Crucell Announces Second Quarter 2006 Results 1/2
   Source: cws.huginonline.com/C/132631/PR/20060...
   PDF: hugin.info/132631/R/1071967/183209.pdf
   
   
   Leiden, The Netherlands, August 29, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, SWX: CRX) today announced its financial results for the first half-year ended June 30, 2006, based on International Financial Reporting Standards (IFRS).
   
   Total revenues for the second quarter were €18.9 million and other operating income was €2.8 million. Net loss for the second quarter of 2006 attributable to equity holders of the parent amounted to €25.7 million. Total revenues for the six months ended June 30, 2006, were €30.6 million; other operating income amounted to €4.8 million for the first six months of 2006. Net loss for the first six months of 2006 attributable to equity holders of the parent amounted to €40.4 million.
   
   Cash and cash equivalents were €177.7 million on June 30, 2006, compared to €178.7 million at the end of the first quarter. Proceeds from the sale of discontinued operations and a reclassification of short-term financial assets to cash, offset cash used in operations in the second quarter. Total assets on June 30, 2006, were €616.1 million.
   
   Crucell's Chief Financial Officer Leonard Kruimer said: "The second quarter results are in line with our expectations as they reflect the effects of purchase price allocation, one-time integration costs, and fully integrated R&D and SG&A costs. Product sales in our Berna subsidiary were up 9% over the same six-month period last year. Given the strong seasonal pattern of these sales, and the expected launch of Quinvaxem(TM), we reiterate our previous guidance for full-year revenue and cash burn: revenue, including other operating income, of €130 to €150 million, with 2006 operational cash burn in the range of €33 to €38 million."
   
   
   Operational Review Second Quarter 2006
   
   * Berna Biotech Acquisition: Crucell's offer for Berna Biotech AG was settled on February 22, 2006. The Company now holds 98.4% of all issued Berna shares. The Company is in the process of delisting the remaining shares, which is expected to be completed in the fourth quarter.
   
   * Quinvaxem: The Korea Food and Drug Administration (KFDA) awarded licensure to Quinvaxem(TM), a fully liquid pentavalent vaccine co-developed with Chiron Corporation, in March 2006. Crucell has started production of the vaccine in Korea and first shipments will be made once pre-qualification is received from the WHO.
   
   * Divestments: Crucell concluded the sale of Rhein Biotech GmbH and veterinary pharmaceuticals company Dr. E. Gräub AG. These divestments enabled Crucell to align its portfolio of activities with its strategic priorities. Total proceeds amounted to €15.4 million.
   
   * Avian influenza vaccine clinical trial: Crucell announced the start of a clinical trial, performed in collaboration with the University of Leicester, UK, testing three types of vaccines against the H9N2 avian influenza virus in humans. The trial involves the vaccination of 560 healthy adults, and will allow Crucell to choose the best vaccine modality for further clinical studies with pandemic flu vaccines. First results of the study are expected by the end of 2006.
   
   * Patent infringement: Crucell settled its patent infringement proceedings against CEVEC Pharmaceuticals GmbH. The final claim in the case was withdrawn following CEVEC's commitment not to use its cell bank in any way that would constitute further infringement of Crucell's European PER.C6?patent.
   
   * STAR(TM) Technology: Crucell signed a non-exclusive STAR(TM) research license agreement with Cambridge, Massachusetts-based Millennium Pharmaceuticals Corporation.
   
   * PER.C6?Licensing: Crucell secured new PER.C6?licensing deals with Upstate USA, BIOA&D and Immuno-Biological Laboratories during the second quarter.
   
   * PER.C6?R&D Center: Crucell and technology partner DSM Biologics announced the establishment of a new PER.C6?R&D Center in Cambridge, Massachusetts, and the appointment of Dr Marco Cacciuttolo as CEO. Operations are expected to commence by the end of 2006.
   
   * Supervisory Board: Mr. Pieter Strijkert, chairman of Crucell's Supervisory Board since the Company's incorporation, stepped down at the Annual General Meeting of Shareholders on June 2, 2006. He was succeeded by the vice-chairman of the Supervisory Board, Mr. Jan Oosterveld.
   
   * Suspension of Aerugen?clinical development: On July 18, 2006, the Company announced the suspension of the clinical development program for Aerugen? a vaccine for the prevention of Pseudomonas aeruginosa infection.
   
   
   Details of the Financial Results First Half-Year
   
   Revenues and Other Operating Income
   Revenues for the first half-year of 2006 were €30.6 million, compared to €13.4 million in the same period last year. Revenues consist of product sales, license revenues and service fees. Revenues in 2006 represent product sales from Berna from the moment of acquisition at February 22, 2006; license revenues and service fees do not include sales from Berna and are therefore included for six months. Product revenues amount to €21.5 million, concentrated in pediatric and travel vaccines. Product revenues are seasonal and have historically been concentrated in the second half of the year. This is due to seasonal sales of influenza vaccine, and the projected sales of the new Quinvaxem(TM) pediatric vaccine. Comparable product sales from Berna in the first half-year 2006 were up 9% over same period last year.
   
   License revenues were €4.6 million, a decrease of €3.7 million over last year. Last year's license revenues included a €2 million milestone and a significant €2 million up-front fee from a partner. License revenue consisted of initial payments from new contracts as well as annual and other payments on existing contracts. Service fees amount to €4.5 million, compared to €5.1 million last year, which represents a slight decrease in chargeable development activities. Service fees represent revenues for product development activities performed under contracts with partners and licensees.
   
   Other Operating income was €4.8 million, compared to €2.6 million in the same period last year. Other operating income consists of government grants, which increased slightly to €3.0 million, and other income of €1.8 million.
   
   Cost of Goods Sold
   Cost of goods sold for the first six months of 2006 amounted to €27.4 million, €24.2 million of which represents product costs and the remainder of €3.2 million represents costs of service activities. The €24.2 million in product costs is relatively high since it includes a €6.4 million inventory purchase price allocation charge. The remaining step-up in inventory on June 30, 2006, as a result of the purchase price allocation, amounts to €11 million, which will be charged to cost of goods sold in future accounting periods.
   
6. [verwijderd] 29 augustus 2006 08:10

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Crucell Announces Second Quarter 2006 Results 2/2Source: cws.huginonline.com/C/132631/PR/20060...
   PDF: hugin.info/132631/R/1071967/183209.pdf
   
   Expenses
   Total expenses consist of research and development (R&D) expenses and selling, general and administrative (SG&A) expenses. Total R&D and SG&A expenses were €48.6 for the first six months of 2006. That represents a €27.1 million increase over the same period last year. The difference is primarily attributable to combining activities of Crucell and Berna since acquisition.
   
   R&D expenses amounted to €29.8 million, which represents a €16.3 million increase over the first half of 2005. Berna clinical programs accounted for a €10.6 million increase in R&D costs in the first six months of 2006. Amortization as a result of the purchase price allocation added €2.1 million in expenses. In addition, costs for clinical development in Leiden for Rabies, West-Nile and Influenza clinical programs added €3.6 million in development costs over same period last year.
   
   SG&A expenses for the first half-year 2006 were €18.8 million and represent an increase of €10.8 million over the first half-year of 2005. Of the increase, €3.5 million represents the addition of the Berna G&A costs to the organization; €4.8 million represents sales & marketing expenses; and €2.5 million represents integration costs, like Sarbanes-Oxley implementation and various advisory costs.
   
   Net Loss
   The Company reported a net loss attributable to equity holders of the parent for the first half-year 2006 of €40.4 million, or €0.75 net loss per share.
   
   Minority interests of €0.5 million represent the share in results of minority shareholders in Berna Biotech AG as well as in Rhein Biotech NV, which is listed at the Frankfurt Exchange (FWB).
   
   Cash Flow and Cash Position
   Cash and cash equivalents increased by €65.9 million in the first six months of 2006 up to an amount of €177.7 million. The net increase is a result of the cash acquired in the acquisition. During the second quarter, cash deposits of €13.0 million were re-classified as restricted cash and serve as collateral for company mortgages and financial leases. These deposits are included on the balance sheet as other financial assets.
   
   Net cash used in operating activities in the first six months of 2006 was €24.1 million. Changes in working capital for the acquired company reflect changes in current assets and current liability balances since the date of acquisition.
   
   Cash from investing activities amounted to €79.3 million. This includes cash acquired in the acquisition of €76.9 million. €9.0 million was used to pay acquisition transaction costs. Proceeds from financial assets include €15.4 million of proceeds from divested assets, Rhein Biotech GmbH and Dr. E. Gräub AG., received in the second quarter. Proceeds from financial assets also include €17.9 million of deposits for which the maturity has decreased to less than 3 months in the second quarter, resulting in a reclassification to cash and cash equivalents.
   
   Net cash from financing activities was €11.0 million, of which €7.9 million represents an increase in mortgage loans and leasing liabilities. The Company has entered and intends to enter into financial leases to finance investment in property, plant and equipment, the effect of which will be to reduce cash outflow in the year the investment takes place. In the first six months the Company received €3.4 million from the issuance of ordinary shares for employee stock options exercised.
   
   Balance Sheet
   Total equity amounts to €464.3 million, of which €11.2 million represents minority interests. A total of 59 million ordinary shares were issued and outstanding on June 30, 2006.
   
   Inventories increased €12.1 million during the second quarter to €62.7 million by June 30, 2006. The increase in inventory is due to purchase of materials for influenza vaccine production in the second half of the year, as well as stock of intermediate and finished goods of Quinvaxem(TM) vaccine.
   
   Short-term financial assets decreased over the second quarter due to a reclassification of €17.9 million of deposits to cash and cash equivalents, since these deposits now have a maturity date of less than 3 months.
   
   Intangible assets amount to €116.2 million and represent acquired in-process R&D; patents and trademarks; and value of customer and supplier relationships. The purchase price allocation has been further updated during the second quarter and is expected to be finalized before year-end.
   
   Investments in Joint venture represent investment in Pevion. The Company's investment in Galapagos NV is classified under "Other financial assets."
   
   Reconciliation IFRS to US GAAP
   Shareholders equity under US GAAP is €413.4 million, €50.9 million lower than under IFRS. This is primarily due to the different method to determine the Berna acquisition price and write-off of in-process R&D of €61.8 million required under USGAAP.
   
   Net loss under US GAAP for the six months ended June 30, 2006, is €102.4 million versus a loss of €40.9 million under IFRS. The difference is mainly due to the write-off of in-process R&D under US GAAP as well as some other minor differences.
   
   Outlook
   The Company maintains its revenue outlook, including other operating income, for 2006 in the €130 to €150 million range, which is dependent on obtaining WHO pre-qualification of the Company's Quinvaxem(TM) vaccine.
   
   2006 will be a year of integration, affecting cash used in operations. Net of integration, one-time transaction costs, investment in plant and equipment and other proceeds from divestitures, the total decrease in cash over 2006 is expected to be in the €33 million to €38 million range. The Company expects to achieve operational cash break-even in 2007.
   
7. [verwijderd] 29 augustus 2006 08:11

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Nieuws ????
8. [verwijderd] 29 augustus 2006 08:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   Jasdanisan schreef:

   -knip-
   

   Hmm, you`re missing some major parts?
   Als je het even verwijderd komt het de leesbaarheid van dit draadje ten goede.
   
   Nu even verder bestuderen in ieder geval van deze nieuwe data. Nog niks schokkends tegengekomen. So far, so good...
9. [verwijderd] 29 augustus 2006 08:14

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Wat zal deze dag ons brengen?
   Ik denk een sterke daling, volgens mij is het wachten op de WHO en kunnen we dan pas zien wat er mogelijk is met Crucell.
   
   mvm
10. [verwijderd] 29 augustus 2006 08:17

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    m van mour schreef:

    Wat zal deze dag ons brengen?
    Ik denk een sterke daling, volgens mij is het wachten op de WHO en kunnen we dan pas zien wat er mogelijk is met Crucell.
    
    mvm
    

    Kortzichtigheid ten top, maar wellicht de typische belegger? Alsof WHO alles is, zie ook eerdere draadjes. Gewoon afwachten, de zekerheid is er en de productie is er klaar voor.
    
    Wachten op het startschot en gelijk verkopen, of dat nu vandaag of morgen is of misschien volgende maand. Dat zal ze bij Crucell denk ik bar weinig uitmaken.
    
    Jammer alleen dat er verwachtingen zijn gewekt, altijd lastig voorspellen in deze sector en heb de voorspellingen altijd afgekeurd. Wellicht op de conference call ( www.companywebcast.nl/webcast//player... ) vandaag meer.
12. [verwijderd] 29 augustus 2006 08:18

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Kan het zijn dat ze dit later vandaag nog naar buiten zullen brengen?
13. $rob$ 29 augustus 2006 08:19

    auteur info

    • $rob$

      Lid sinds: 01 jan 2000

      Laatste bezoek: 14 apr 2025

    • Aanbevelingen

      Ontvangen: 260

      Gegeven: 65

    •    Aantal posts: 1.976

    quote:

    m van mour schreef:

    Wat zal deze dag ons brengen?
    Ik denk een sterke daling, volgens mij is het wachten op de WHO en kunnen we dan pas zien wat er mogelijk is met Crucell.
    
    mvm
    

    Nog een koopjesjager....
14. [verwijderd] 29 augustus 2006 08:23

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Winst hoger dan gemiddelde van (2) analisten.
    Omzet lager dan gemiddelde analisten.
    Nauwelijks extra cash-burn door verkoop van activiteiten.
    Pre-opening op € 16,30, -/- 1,6%.
    Slotkoers vandaag? € 17,20 is mijn inschatting.
15. [verwijderd] 29 augustus 2006 08:25

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    m van mour schreef:

    Wat zal deze dag ons brengen?
    Ik denk een sterke daling, volgens mij is het wachten op de WHO en kunnen we dan pas zien wat er mogelijk is met Crucell.
    
    mvm
    

    daling? ow ja...het is cijferdag
    
    dan gaat het namelijk 9 van de 10 keer fout........
16. [verwijderd] 29 augustus 2006 08:26

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Laatste dag van de uitverkoop vóór het nieuwe seizoen...vraag niet hoe het kan maar profiteer er van...OP=OP....!
    gr
    Janh1
17. [verwijderd] 29 augustus 2006 08:28

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Eerst de spike naar 14.75!
    Daarna sluiten op 4-day-high!
    
    sammie
18. [verwijderd] 29 augustus 2006 08:29

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Mijn stukjes krijgen ze niet. Crucell ligt op koers!
    
    KB.
19. [verwijderd] 29 augustus 2006 08:29

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik verwacht een lichte stijging-daling van de koers vandaag. Oftewel "stabiel".
    Wel veel volatiliteit gedurende de dag.
    De blokken die nu in de pre-opening staan zeggen niets.......
    
    Grtz,
    ZEKER
20. Hans Igor 29 augustus 2006 08:30

    auteur info

    • Hans Igor

      Lid sinds: 01 jan 2000

      Laatste bezoek: 13 apr 2025

    • Aanbevelingen

      Ontvangen: 548

      Gegeven: 869

    •    Aantal posts: 1.594

    quote:

    wilb52 schreef:

    Eerst de spike naar 14.75!
    Daarna sluiten op 4-day-high!
    
    sammie
    

    Je zou wel weer eens helemaal gelijk kunnen krijgen, Sammie. Er is 1 partij aan het kloten, maar er zullen er toch ook zijn die dit koopje niet laten lopen.
    Gr.
    Hans Igor
    Go Grand-Cru-cell!!!
    
21. [verwijderd] 29 augustus 2006 08:35

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Hans Igor schreef:

    [quote=wilb52]
    Eerst de spike naar 14.75!
    Daarna sluiten op 4-day-high!
    
    sammie
    [/quote]
    Je zou wel weer eens helemaal gelijk kunnen krijgen, Sammie. Er is 1 partij aan het kloten, maar er zullen er toch ook zijn die dit koopje niet laten lopen.
    Gr.
    Hans Igor
    Go Grand-Cru-cell!!!
    
    

    En ook Hans heeft volgens mij helemaal gelijk, vroeger nog weleens onder de indruk van de grapjassen in het boekje voorbeurs. Maar we gaan gewoon redelijk openen en een volatiel dagje tegemoet.
    
    Als altijd zijn (helaas) de analisten meningen van belang. Zo ook de conference call, wat word er gezegd, beloofd en wellicht zelfs teruggenomen...